AI English summary of an SEC filing — figures as filed

Cardinal Health said its Board elected Robert W. Azelby as a director on February 28, 2024, effective March 1, 2024, to serve until the 2024 annual meeting of shareholders.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Feb 28, 2024Period of report Feb 28, 2024Summary published (UTC) Oct 28, 2026

Key points

AI summary

Cardinal Health said its Board elected Robert W. Azelby as a director on February 28, 2024, effective March 1, 2024, to serve until the 2024 annual meeting of shareholders.
The company said the Board affirmatively determined that Azelby is independent under New York Stock Exchange and Exchange Act rules, and assigned him to the Board's Risk Oversight Committee.
Cardinal Health said Azelby will receive compensation consistent with that of its other non-employee directors. It said there are no arrangements or understandings between Azelby and any other person under which he was appointed, and no transactions currently require disclosure under Item 404(a) of Regulation S-K.
The company said Azelby has more than 30 years of experience, including service as President and CEO of Eliem Therapeutics, CEO of Alder BioPharmaceuticals and Chief Commercial Officer of Juno Therapeutics, and that he spent 15 years at Amgen.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Board Election and Effective Date

Cardinal Health said its Board elected Robert W. Azelby as a director on February 28, 2024, effective March 1, 2024, to serve until the 2024 annual meeting of shareholders.

Source · Based on the filing body and exhibits

Independence Determination and Committee Assignment

The company said the Board affirmatively determined that Azelby is independent under New York Stock Exchange and Exchange Act rules, and assigned him to the Board's Risk Oversight Committee.

Source · Based on the filing body and exhibits

Director Compensation and No Appointment Arrangements

Cardinal Health said Azelby will receive compensation consistent with that of its other non-employee directors. It said there are no arrangements or understandings between Azelby and any other person under which he was appointed, and no transactions currently require disclosure under Item 404(a) of Regulation S-K.

Source · Based on the filing body and exhibits

Azelby's Experience and Other Board Seats

The company said Azelby has more than 30 years of experience, including service as President and CEO of Eliem Therapeutics, CEO of Alder BioPharmaceuticals and Chief Commercial Officer of Juno Therapeutics, and that he spent 15 years at Amgen.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.